Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:41:32.374Z.
Calculation as of: 2026-10-06T15:41:32.374Z.
Quote observation: 2026-10-06T15:39:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
PE RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.23M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.23M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.25M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | 4.85 | 10.48 | 10.48 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.08M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.47M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.52M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.69M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.63M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
